Segment Reporting

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Segment Reporting

13.   Segment Reporting. We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and OEM. Within these product categories, we sell a variety of products, including cardiology and radiology devices (which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases), as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on net sales and operating income.

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three and nine-month periods ended September 30, 2020 and 2019, were as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2020		2019		2020		2019
Net Sales
Cardiovascular	$	236,413	$	234,426	$	684,134	$	711,570
Endoscopy		7,562		8,623		21,737		25,360
Total net sales		243,975		243,049		705,871		736,930
Operating Income (Loss)
Cardiovascular		(1,702)		(6,210)		(20,662)		11,263
Endoscopy		1,766		3,329		3,093		7,581
Total operating income (loss)		64		(2,881)		(17,569)		18,844
Total other expense - net		(2,248)		(2,809)		(8,907)		(8,689)
Income tax (benefit) expense		825		(2,292)		(1,255)		499
Net income (loss)	$	(3,009)	$	(3,398)	$	(25,221)	$	9,656